Symmetry-guided fusion converts weak liver pyruvate kinase inhibitors into potent allosteric activators
Year: 2026
Type: article
Abstract: Structure-guided exploitation of symmetry within multimeric protein interfaces offers an opportunity to convert partial ligand-binding poses into higher-affinity modulators. Here, we report a class of symmetrical "Z-shaped" allosteric activators of human liver pyruvate kinase (PKL), generated by symmetry-guided fusion of binding poses identified in inhibitor-bound crystal structures. The resulting ligands span the inter-subunit pocket at the tetrameric dimer-dimer interface and display substantially enhanced activity, with several analogues showing nanomolar activation potency. In HepG2 PKM2-knockout cells, the compounds increased PKL activity, maximal mitochondrial respiratory capacity and glycolytic proton efflux without altering PKL expression, Ser113 phosphorylation-dependent localisation, cell proliferation or triglyceride accumulation under the conditions examined. These findings establish symmetry-guided ligand fusion as a productive design strategy in this PKL system and provide structurally defined chemical tools for investigating the metabolic consequences of direct PKL activation.
Source: RSC Medicinal Chemistry
DOI: 10.1039/d6md00604c
Authors: Leticia Monjas(Conceptualization, Methodology), Alexandra Rodriguez Rivero(Conceptualization, Methodology), Anders Foller Füchtbauer(Methodology), Oscar Nilsson(Methodology, Writing – original draft), Liliana Håversen(Methodology), Aleksei Lulla(Methodology), Paul Brear, Mikael Rutberg(Methodology), Per-Olof Bergh, Jan Borén(Conceptualization), Adil Mardinoglu, Marko Hyvönen(Conceptualization), Morten Grøtli(Conceptualization)
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7214242295
